Identification and Characterization of a Novel Epitope of ASFV-Encoded dUTPase by Monoclonal Antibodies

Deoxyuridine 5′-triphosphate nucleotidohydrolase (dUTPase) of African swine fever virus (ASFV) is an essential enzyme required for efficient virus replication. Previous crystallography data have indicated that dUTPase (E165R) may serve as a therapeutic target for inhibiting ASFV replication; however, the specificity of the targeting site(s) in ASFV dUTPase remains unclear. In this study, 19 mouse monoclonal antibodies (mAbs) were produced, in which four mAbs showed inhibitory reactivity against E165R recombinant protein. Epitope mapping studies indicated that E165R has three major antigenic regions: 100–120 aa, 120–140 aa, and 140–165 aa. Three mAbs inhibited the dUTPase activity of E165R by binding to the highly conserved 149–RGEGRFGSTG–158 amino acid sequence. Interestingly, 8F6 mAb specifically recognized ASFV dUTPase but not Sus scrofa dUTPase, which may be due to structural differences in the amino acids of F151, R153, and F154 in the motif V region. In summary, we developed anti-E165R-specific mAbs, and identified an important antibody-binding antigenic epitope in the motif V of ASFV dUTPase. Our study provides a comprehensive analysis of mAbs that target the antigenic epitope of ASFV dUTPase, which may contribute to the development of novel antibody-based ASFV therapeutics.

[1]  A. Fujioka,et al.  dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA‐repair‐defective human cancer cells , 2020, Cancer science.

[2]  S. Kitazume,et al.  Identification of a herpes simplex virus 1 gene encoding neurovirulence factor by chemical proteomics , 2020, Nature Communications.

[3]  Jin-ding Chen,et al.  Current State of Global African Swine Fever Vaccine Development under the Prevalence and Transmission of ASF in China , 2020, Vaccines.

[4]  S. Cedrés,et al.  A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer , 2020, Investigational New Drugs.

[5]  H. Qiu,et al.  Current status and evolving approaches to African swine fever vaccine development. , 2020, Transboundary and emerging diseases.

[6]  G. Gao,et al.  Cryo-EM Structure of the African Swine Fever Virus. , 2019, Cell host & microbe.

[7]  Z. Rao,et al.  Architecture of African swine fever virus and implications for viral assembly , 2019, Science.

[8]  F. Freitas,et al.  An Update on African Swine Fever Virology , 2019, Viruses.

[9]  M. Ariza,et al.  Epstein-Barr Virus dUTPase Induces Neuroinflammatory Mediators: Implications for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. , 2019, Clinical therapeutics.

[10]  L. Dixon,et al.  African swine fever. , 2019, Antiviral research.

[11]  J. Bao,et al.  Genome comparison of African swine fever virus China/2018/AnhuiXCGQ strain and related European p72 Genotype II strains. , 2019, Transboundary and emerging diseases.

[12]  H. Ueno,et al.  First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors , 2018, Investigational New Drugs.

[13]  J. Bao,et al.  Molecular Characterization of African Swine Fever Virus, China, 2018 , 2018, Emerging infectious diseases.

[14]  Vinicius M. Alves,et al.  QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial and Transmission Blocking Activities , 2018, Front. Pharmacol..

[15]  J. Szabó,et al.  Cross-species inhibition of dUTPase via the Staphylococcal Stl protein perturbs dNTP pool and colony formation in Mycobacterium. , 2015, DNA repair.

[16]  S. Lemeshow,et al.  Antibody to Epstein-Barr Virus Deoxyuridine Triphosphate Nucleotidohydrolase and Deoxyribonucleotide Polymerase in a Chronic Fatigue Syndrome Subset , 2012, PloS one.

[17]  A. Fujioka,et al.  1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors. , 2012, Journal of medicinal chemistry.

[18]  A. Fujioka,et al.  Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors. , 2012, Journal of medicinal chemistry.

[19]  I. Gilbert,et al.  Design, Synthesis, and Evaluation of 5′‐Diphenyl Nucleoside Analogues as Inhibitors of the Plasmodium falciparum dUTPase , 2011, ChemMedChem.

[20]  I. Simon,et al.  Nucleotide pyrophosphatase employs a P-loop-like motif to enhance catalytic power and NDP/NTP discrimination , 2011, Proceedings of the National Academy of Sciences.

[21]  Ian H. Gilbert,et al.  β-Branched acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. , 2011, Bioorganic & medicinal chemistry.

[22]  T. Mettenleiter,et al.  Live vaccination with an H5-hemagglutinin-expressing infectious laryngotracheitis virus recombinant protects chickens against different highly pathogenic avian influenza viruses of the H5 subtype. , 2009, Vaccine.

[23]  I. Gilbert,et al.  Design, synthesis and evaluation of novel uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP nucleotidohydrolase. , 2009, European journal of medicinal chemistry.

[24]  R. Glaser,et al.  The EBV-Encoded dUTPase Activates NF-κB through the TLR2 and MyD88-Dependent Signaling Pathway1 , 2009, The Journal of Immunology.

[25]  S. Lemeshow,et al.  Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: Evidence for depression-induced atherosclerotic risk , 2008, Brain, Behavior, and Immunity.

[26]  G. F. Ruda,et al.  Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase. , 2006, Journal of medicinal chemistry.

[27]  Duilio Cascio,et al.  Crystal structure of the Mycobacterium tuberculosis dUTPase: insights into the catalytic mechanism. , 2004, Journal of molecular biology.

[28]  Z. Dauter,et al.  Crystal structure of dUTPase from equine infectious anaemia virus; active site metal binding in a substrate analogue complex. , 1999, Journal of molecular biology.

[29]  D. McRee,et al.  Crystal structure of dUTP pyrophosphatase from feline immunodeficiency virus , 1996, Protein science : a publication of the Protein Society.

[30]  P. Nyman,et al.  Kinetic Characterization of dUTPase from Escherichia coli * , 1996, The Journal of Biological Chemistry.

[31]  B. Vértessy,et al.  Specific derivatization of the active site tyrosine in dUTPase perturbs ligand binding to the active site. , 1996, Biochemical and biophysical research communications.

[32]  T. Mettenleiter,et al.  Identification and characterization of pseudorabies virus dUTPase , 1996, Journal of virology.

[33]  Zbigniew Dauter,et al.  Crystal structure of a dUTPase , 1992, Nature.